HPAPI & Payload Synthesis
Abzena has expertise in both chemical payloads and linkers that enables us to provide our customers with a broad range of linker-payload combinations and reagents for screening at Abzena or elsewhere. Our payload resources include a toolbox of highly potent cytotoxic payloads (HPAPIs) with different mechanisms of action for use in the development of ADCs. Our new manufacturing facility in Bristol is capable of handling HPAPIs up to an OEL of 10ng/m3 (Abzena Band 5).
- Akt Inhibitors e.g. GDC-0068
- DNA Transcription e.g. Dactinomycin
- DNA cross-linking agents, such as Mitomycin C
- Dihydrofolate Reductase (DHFR) Inhibitors such as Methotrexate
- DNA Intercalators, including Doxorubicin HCL and Epirubicin HCL
- Microtubule Inhibitors e.g Dolastatin-10 & Auristatins
In addition to our toolbox, Abzena can design and synthesise custom combinations of potent cytotoxic payloads and linkers or provide guidance and advise on selection of payloads.
Abzena can use its broad range of payloads in conjunction with its linker technologies to create a range of unique ADCs with different payloads, that can be screened by Abzena, our customers or by third parties. We can also provide linker, antibody and payload reagents to third party companies.
Working with Abzena
Abzena’s HPAPI and payload synthesis services are tailored to each project to ensure that the objectives are met or exceeded.
We collaborate with a wide range of organisations from virtual companies through to big pharma, including many of the world’s top companies, as well as academic research groups from across the globe.
To get more information, a quote or to schedule a teleconference please contact us.